1. Generics Bulletin
  2. >>Business
  3. >>Deals

Ajinomoto Buys Out Granules India From JV

 
• By Penelope MacRae

Ajinomoto Bio-Pharma Services has announced it is buying out partner Granules India from an API manufacturing joint-venture based in southern India as the company seeks to integrate its small- and large-molecule businesses and provide more seamless customer service.

India - Japan
The Indian Joint Venture was struck between India’s Granules and Japan’s Ajinomoto • Source: Shutterstock

Contract development and manufacturing organization Ajinomoto Bio-Pharma Services is buying out partner Granules India to take full control of their Indian active pharmaceutical ingredient manufacturing joint venture. The acquisition is part of Ajinomoto Bio-Pharma’s strategy to offer a “more seamless” support supply-chain to its biopharmaceutical corporate customers, reflecting what is become a growing CDMO industry trend.

Ajinomoto Bio-Pharma – a wholly owned subsidiary of Tokyo-based Ajinomoto – and Granules India currently each own 50% of the API company, Granules OmniChem Pvt Ltd, based in Visakhapatnam in southern India

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By Adam Zamecnik

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By Adam Zamecnik

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

More from Business

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.